Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

If these pre-market losses hold, Moderna stock could erase part of its 8.1% year-to-date lead and deepen its 57.1% year-over-year loss. The equity may also slip below a critical technical level -- its 20-day moving average -- which could pressure it toward its Jan.